Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance

O’Reilly, John; Jones, Melvyn; Parnham, Jill; Lovibond, Kate; Rudolf, Michael

doi:10.1136/bmj.c3134

Cited by 61 publications

(48 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An as-needed inhaled short-acting β-agonist is generally the first medication initiated, often with a standing dose of an inhaled long-acting bronchodilator [9]. However, the optimal long-acting bronchodilator regimen is unknown.…”

Section: Standard Pharmacological Therapiesmentioning

confidence: 99%

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

et al. 2015

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and resource use worldwide. The goal of this official American Thoracic Society (ATS)/European Respiratory Society (ERS) research statement is to describe evidence related to diagnosis, assessment and management; identify gaps in knowledge; and make recommendations for future research. It is not intended to provide clinical practice recommendations on COPD diagnosis and management.Clinicians, researchers, and patient advocates with expertise in COPD were invited to participate. A literature search of Medline was performed, and studies deemed relevant were selected. The search was not a systematic review of the evidence. Existing evidence was appraised and summarised, and then salient knowledge gaps were identified.Recommendations for research that addresses important gaps in the evidence in all areas of COPD were formulated via discussion and consensus.Great strides have been made in the diagnosis, assessment and management of COPD, as well as understanding its pathogenesis. Despite this, many important questions remain unanswered. This ATS/ ERS research statement highlights the types of research that leading clinicians, researchers, and patient advocates believe will have the greatest impact on patient-centred outcomes. @ERSpublications ATS/ERS statement: which types of research will have the greatest future impact on patientcentred outcomes in COPD? http://ow.ly/I54Hb

show abstract

Section: Standard Pharmacological Therapiesmentioning

confidence: 99%

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

et al. 2015

View full text Add to dashboard Cite

show abstract

“…According to the guidelines for the management of COPD published by the British National Institute for Health and Clinical Excellence (NICE) (O'Reilly et al, 2010), the treatment choice after initial SABA or SAMA bronchodilation for persistent breathlessness or exacerbations is determined by the level of post bronchodilator FEV 1 . If the FEV 1 is Ͼ50%, then the recommendation is to use a LAMA such as tiotropium bromide or a LABA such as salmeterol or formoterol.…”

Section: The Role Of Bronchodilators In the Management Of Asthmmentioning

confidence: 99%

Pharmacology and Therapeutics of Bronchodilators

et al. 2012

View full text Add to dashboard Cite

“…This is reflected by the increasing prominence of pulmonary rehabilitation in respiratory disease guidelines. 13,14 Through the deeper understanding of the cellular mechanisms of muscle wasting, there have been notable advances in the development of potential therapeutic anabolic and anti-catabolic drugs, which are described in detail by Evans (REF Evans review). Although these drugs will eventually be used more broadly for muscle dysfunction in non-respiratory populations (e.g.…”

mentioning

confidence: 99%

Aspects of skeletal muscles in chronic respiratory disease

Man

2016

Chron Respir Dis

View full text Add to dashboard Cite

This review series examines current aspects in the aetiology, assessment and management of skeletal muscle dysfunction in chronic respiratory disease. The reader may wonder why this is of interest in disorders where the lung is the primary organ of impairment. First, skeletal muscle dysfunction is one of the commonest extra-pulmonary manifestations in chronic respiratory disease. Previous cross-sectional studies have estimated that approximately a third of individuals with chronic obstructive pulmonary disease (COPD) have significant quadriceps muscle weakness, 1 while 15% have evidence of sarcopenia.

show abstract

Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance

Cited by 61 publications

References 15 publications

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

Pharmacology and Therapeutics of Bronchodilators

Aspects of skeletal muscles in chronic respiratory disease

Contact Info

Product

Resources

About